Viral diseases are significant impediments to the sustainability of shrimp aquaculture. In addition to endemic disease, new viral diseases continue to emerge and cause significant impact on the shrimp industry. Disease caused by infectious myonecrosis virus (IMNV) has caused tremendous losses in farmed Pacific white shrimp (Litopenaeus vannamei) since it emerged in Brazil and translocated to Indonesia. There are no existing antiviral interventions, outside of pathogen exclusion, to mitigate disease in commercial shrimp operations. Here, we describe an iterative process of panning the genome of IMNV to discover RNA interference trigger sequences that initiate a robust and long-lasting protective response against IMNV in L. vannamei. Using this process, a single, low dose (0.02 mg) of an 81 or 153 bp fragment, with sequence corresponding to putative cleavage protein 1 in ORF1, protected 100 % of animals from disease and mortality caused by IMNV. Furthermore, animals that were treated with highly efficacious dsRNA survived an initial infection and were resistant to subsequent infections over 50 days later with a 100-fold greater dose of virus. This protection is probably sequence dependent, because targeting the coding regions for the polymerase or structural genes of IMNV conferred lesser or no protection. Interestingly, non-sequence specific dsRNA did not provide any degree of protection to animals as had been described for other shrimp viruses. Our data indicate that the targeted region for dsRNA is a crucial factor in maximizing the degree of protection and lowering the dose required to induce a protective effect against IMNV infection in shrimp.
INTRODUCTION
Viral diseases that impact cultured shellfish are a considerable impediment to successful, sustainable aquaculture practices and trade, and have the most profound economic impact in developing, tropical countries that provide optimal climate and habitat for shrimp aquaculture. The Pacific white shrimp, Litopenaeus vannamei (Decapoda: Penaeidae), is uniquely amenable to aquaculture and has rapidly become the dominant farmed shrimp species globally; indeed, production of L. vannamei increased from 8000 mt in 1980 to 1.38610 6 t in 2004 worldwide (FAO, 2009) . Pathogen translocation and disease outbreaks have ensued with increasing production, and significant economic losses have resulted with the emergence of each of the major viral pathogens (Walker & Winton, 2010) . Epizootics of viral diseases in particular cause substantial mortality in L. vannamei and result in devastating financial losses; it has been estimated that annual losses globally as a result of diseases (mostly viral in aetiology) have been as high as 3 billion USD (Lightner, 2003; Walker & Mohan, 2009) . The occurrence of a pathogenic virus in a pond of growing shrimp exerts a range of consequences, including forcing the grower to prematurely harvest, increasing production costs through decreased feed conversion or causing a complete loss of animals (Walker & Winton, 2010) . Beyond deliberate pathogen exclusion or selective breeding, which is not effective against all viral pathogens, there are no means to control or treat viral disease and prevent perpetual transmission in farmed shrimp. A practical and efficacious means of protecting shrimp against viral disease would offset these losses and facilitate more profitable production of farmed shrimp in this multibillion dollar per year industry.
RNA interference (RNAi) is a promising and emerging approach to shrimp disease control (Hirono et al., 2011; Krishnan et al., 2009; Robalino et al., 2005 Robalino et al., , 2007 Shekhar & Lu, 2009) . RNAi results in RNA degradation thereby preventing gene expression. RNAi triggers, including small interfering RNAs (siRNA) and dsRNAs, can be provided exogenously to arthropod cells to suppress a gene of interest in a sequence-specific manner. It is likely that RNAi evolved, in part, as an antiviral response. Indeed, the RNAi phenomenon also has been observed as an antiviral response in mosquitoes that transmit human viral pathogens and has been proposed as a transmission-blocking strategy in which transgenic mosquitoes, expressing an RNAi trigger in the form of an inverted-repeat of the dengue virus genome, no longer support amplification and transmission of the virus (Franz et al., 2006) . There is evidence that the requisite RNAi machinery is present and functioning in a similar manner in penaeid shrimp (Dechklar et al., 2008; Su et al., 2008; Unajak et al., 2006) . Therefore, RNAi is an attractive means to specifically disable virus infection in shrimp cells and thereby protect shrimp from associated pathology and morbidity. Indeed specific RNAi triggers mitigate disease caused by white spot syndrome virus (WSSV) (Robalino et al., 2005; Xu et al., 2007) , yellowhead virus (YHV) (Tirasophon et al., 2005 (Tirasophon et al., , 2007 Yodmuang et al., 2006) and taura syndrome virus (TSV) (Robalino et al., 2004) .
Infectious myonecrosis virus (IMNV) is a non-enveloped, dsRNA virus that is a member of the family Totiviridae. IMNV was first discovered in 2003 after a severe disease outbreak in 2002 in Brazil that was characterized by high mortality and animals exhibiting necrosis in the tail muscle (Poulos et al., 2006) . In previous outbreaks, mortality has ranged from 40 to 70 % and occurs over the course of the 90-120 days in which animals are in ponds (Andrade et al., 2007) . Moribund animals have ever-increasing opaque to white muscle tissue visible through the cuticle, starting in the ventral portion of the muscle and expanding dorsally in each abdominal segment. Histopathologically, animals demonstrate a characteristic coagulative necrosis of skeletal muscle with fluid accumulation between muscle fibres and pronounced hypertrophy of the lymphoid organ due to formation of spheroids, well-delineated non-tubular aggregates of lightly basophilic cells that are common to several virus infections that affect shrimp (Poulos et al., 2006) . (Senapin et al., 2007) ; this translocation of the pathogen is evidence for a very real risk for spread throughout Asia and the world. Due to the current and tremendous future potential impact this disease has on the shrimp industry, development of a vaccine or mitigation strategy is prudent. The aim of this work was to discover and optimize RNAi trigger sequences that would elucidate a protective response to IMNV. We describe an iterative process of panning the IMNV genome for antiviral sequences through which we arrived upon a targeted RNAi trigger for a short, precise portion of the 59 end of the IMNV genome that confers long-lasting and robust protection against IMNV when administered in a single, low dose.
IMNV reached Indonesia in 2006

RESULTS
A disease challenge model was established that uses an intramuscular injection of a clarified virus preparation; this protocol yields consistent morbidity, mortality and pathology in infected animals. IMNV challenge resulted in 100 % mortality, with variation of duration to mortality according to dose (Fig. 1) . A 100-fold dilution of the tissue homogenate resulted in 100 % mortality over an 18 day period and was used as the virus challenge dose. Quantitative RT-PCR (RTqPCR) provided evidence of virus replication because virus genome copy numbers ranged from 2.5610 5 to 3.5610 7 IMNV copy numbers ml 21 in muscle tissues sampled at day 9 post-infection (p.i.) when compared with the inoculum dose (3.2610 3 IMNV copy numbers ml
21
). These RT-qPCR results support histopathological observations, because histopathology sections from moribund animals collected from this same experiment showed characteristic IMNV pathology ( Supplementary Fig. S1 , available in JGV Online). Negative control animals that were injected with sterile 2 % NaCl (virus diluent) showed no signs of histopathological Fig. 1 . Shrimp survival post-challenge with serial dilutions of purified IMNV was measured to establish a challenge dose for antiviral efficacy trials. Shrimp weighing 8-10 g were injected into the third abdominal segment with 100 ml stock virus, 10 or 100¾ dilution or 2 % physiological saline (sham). Mortality was measured daily for 18 days at which point there were no surviving viruschallenged animals. n520 shrimp for each group.
Developing a dsRNA antiviral for IMNV in shrimp muscle lesions or trauma at the injection site, and the presence of IMNV was not detected in this group by RTqPCR.
Three regions that encompass portions of the 59, centre and 39 regions of the IMNV genome were chosen as targets for dsRNA design (Fig. 2) ; these are designated dsRNA95-475, dsRNA3764-4805 and dsRNA5518-6391 according to the range of nucleotides represented from the genome (GenBank accession no. EF061744). dsRNAs were injected into shrimp at a 2.0 mg dose; animals were infected with IMNV 2 days later, using the established challenge model. Control shrimp were subjected to heterologous dsRNA or sham-inoculation and subsequently challenged with IMNV, and showed significant mortality with 1.67 and 3.33 % survival, respectively. Of the animals subjected to IMNVspecific dsRNAs, 81.67 and 61.67 % in the dsRNA95-475 and dsRNA3764-4805 groups survived IMNV infection for the duration of the experiment (30 days), respectively; this is a statistically significant difference (P,0.001) in survivorship as compared with controls. During the course of the experiments (days 12 and 13), significant differences in survival were evident between animals inoculated with dsRNA5518-6391 and dsRNAeGFP (P50.008 and P50.034, respectively), but not between dsRNAeGFP and the sham inoculation groups (P50.183 and P50.108). By day 30, however, animals injected with dsRNA5518-6391 had similar mortality to the controls with 5 % survival postchallenge; no significant difference was evident between survival in animals injected with dsRNA5518-6391, dsRNAeGFP or the 2 % saline control inoculation. All of the non-infected controls survived for the duration of the experiment (Fig. 3) . Further, RT-qPCR on muscle tissues sampled from dead individuals (n54 per treatment) at 9-14 days p.i. demonstrated a significant reduction in genome copy number between animals administered either dsRNA95-475 or dsRNA3764-4805 (mean 2. (Fig. 4) .
To test the longevity of the protective effect, a group of dsRNA95-475-injected shrimp (n517) from the initial target specificity assay was subjected to a second infection at 100-fold higher dose, 52 days after the initial virus challenge and 54 days after the administration of dsRNA. Animals were followed for an additional 40 days after secondary challenge (94 days from the start of the experiment) and showed 94 % survival (16/17), as compared with 10 challenge control animals that showed 100 % mortality (10/10) within 8 days.
dsRNA95-475 and dsRNA3764-4805, which provided the highest levels of protection, were used in a dose titration study to determine the minimal dose to achieve protection from IMNV challenge. Animals were injected with 2.0, 0.2 or 0.02 mg dsRNA95-475 or dsRNA3764-4805, then challenged 2 or 10 days post-inoculation of dsRNA with IMNV. As shown in Fig. 5 , 80 % of animals receiving dsRNA95-475 were protected from IMNV challenge even at the lowest dose (0.02 mg) and when challenged 10 days post-injection of dsRNA. dsRNA3764-4805 elicited this level of protection but only when animals were injected with 10 times the amount of dsRNA (0.2 mg) (Fig. 5 ).
Moribund animals were sampled for histopathological analysis from sham-vaccinated controls, dsRNAeGFP administered controls, and the low dose (0.02 mg) of dsRNA3764-4805 at both 2 and 10 days post-administration of dsRNA. Evidence of IMNV infection and disease included extensive necrosis of muscle fibres, distributed in small to large irregular foci scattered throughout the tail. The lesions were consistent with histopathological changes described previously as characteristic of IMNV infection (Poulos et al., 2006) . Both acute and chronic lesions were evident, often in adjacent locations. Acute lesions were characterized by coagulative necrosis and fragmentation of muscle bundles. Infiltration of haemocytes was mostly limited to small clusters scattered along the connective tissue septa that separated groups of muscles. Chronic lesions were characterized by partial or total loss of myofibres with condensation/contraction of the fibrous connective tissue components. Haemocyte infiltrates in Fig. 2 . Diagram of the IMNV genome transcription and translation products (modified from Nibert, 2007) showing regions targeted for RNAi. Predicted protein products are indicated by dark grey lines (predicted proteins 1-3) or grey shading (major capsid protein and RdRp). Target regions for dsRNA production are indicated as thick black lines with corresponding nucleotide regions. Longer length dsRNAs that were generated to proteins 1 and 2 encoding sequence included two iterations truncated by~100 bp on either side (193-475 and 95-376) . Shorter dsRNAs generated within the protein 1 encoding region are magnified (bottom left).
chronic lesions were minimal in contrast to a previous report (Poulos et al., 2006) . Lymphoid organ spheroid formation was evident and usually prominent in all lymphoid organs examined, with multiple spheroids affecting most of the organ. In contrast to histopathological observations in IMNV-infected control animals, muscle lesions in the dsRNA-injected shrimp that were sacrificed at termination of the trial were chronic in appearance. Acute muscle necrosis was not evident in most of these animals, but was limited to a few very small foci in an occasional animal. In addition, two animals that were rechallenged with additional virus and examined by histopathology showed mature fibrous scar tissue with no necrotic lesions.
Because dsRNA95-475 provided significant (P50.0003 in comparison with controls), long-term protection from IMNV-induced disease, and was highly protective even at a low dose, this region was further scrutinized for development of shorter dsRNAs as depicted in Fig. 2 . Two dsRNAs were generated as~100 bp truncations from the 59 or 39 (95-376) end of the original dsRNA95-475 dsRNA. When administered 10 days prior to challenge, dsRNA95-376 conferred 100 % protection (P,0.0001), whereas the 59 truncation (193-475) conferred 93.33 % protection in animals 30 days post-administration of dsRNA (P,0.0001). Shorter dsRNAs were then designed within this truncated region to the 194-275, 219-273, and 223-376 regions of the IMNV genome (Fig. 2) . Of these, dsRNA194-275 and 223-376 injected animals showed 100 % survival (P,0.0001) and dsRNA219-273 provided 73.33 % protection (P50.0005) following IMNV challenge (Fig. 6) . Fig. 3 . Shrimp survival post-administration of candidate antiviral dsRNAs corresponding to virus gene targets and post-infection with IMNV. Animals were inoculated with 2.0 mg dsRNA at day 0, then challenged with virus 2 days later. Positive control animals received an inoculation containing an equivalent volume of RNase-free water at day 0. Negative control animals received an equivalent volume of 2 % saline (viral diluent) on day 2. The dsRNA target position on the IMNV genome or heterologous dsRNA (eGFP) is indicated (see Fig. 2 ). Animal survival (displayed as a per cent of the total animals per study group, y-axis) was monitored daily after dsRNA administration (x-axis). Three replicates of 20 animals (n560) weighing 5-7 g were used for each treatment group. At day 30, groups subjected to treatment with dsRNA95-475 and dsRNA3764-4805 were significantly different in survivorship from controls (P,0.001); no significant difference was evident between survival in animals injected with dsRNA5518-6391, dsRNAeGFP or the 2 % saline control. Fig. 4 . RT-qPCR analysis of virus load in muscle tissue of animals subjected to candidate antiviral dsRNAs and IMNV infection. Tissues were collected from animals that died between 9 and 14 days postchallenge. dsRNA-inoculated groups are indicated by the target position on the IMNV genome. The y-axis indicates log viral genome copy number calculated from an RNA standard curve generated per Andrade et al. (2007) . Bars represent standard error between samples (n54 shrimp per treatment). 
DISCUSSION
These studies describe the first use of RNAi to protect shrimp from IMNV, a significant emerging shrimp pathogen. Three target regions, spanning the length of the IMNV genome, were selected as initial targets for dsRNA generation. The dsRNA95-475, and several truncations of this region, targeting the 59-most end of the IMNV genome provided the greatest protection from disease in terms of dose and duration. This genome region encompassed therein encodes predicted protein 1 and the N-terminal portion of predicted protein 2 (Fig. 2) , the former of which is postulated to play a role in host immune suppression, potentially by suppressing host RNAi machinery (Nibert, 2007) . By analogy, pathogenic RNA viruses of other invertebrate species encode proteins that have dsRNA binding activity and modify or inhibit the host RNAi response (Li et al., 2002; van Rij et al., 2006) . If dsRNA95-475 (or truncations thereof) do not function by suppressing a suppressor of RNAi, it is possible that the antiviral effect is more potent because of accessibility of the 59 portion of the genome as was observed for small hairpin RNA vectors developed to target the hepatitis B virus genome (Sun et al., 2010) . dsRNA targeting the central and 39 regions of the genome provided less protection from IMNV-induced disease. dsRNA3764-4805 that targets the major capsid protein sequence, provides a significant, but intermediate, protective effect. This is an interesting finding because dsRNA corresponding to structural proteins (VP19 and VP28) of WSSV a large DNA virus, are very effective in reducing mortality when administered before challenge (Robalino et al., 2004) . Specific targeting of the non-structural RNA-dependent RNA polymerase (RdRP) protein using dsRNA5518-6391 provided no measurable protection. This is in contrast to previous work that demonstrated effective protection from infection when non-structural and after infection with IMNV. Animals were inoculated with 2.0, 0.2 or 0.02 mg dsRNA at day 0 and were challenged at day 10. Control animals (c) were injected at day 0 with dsRNAeGFP, or an equivalent volume of RNase-free water (positive control), or with an equivalent volume of 2 % saline at day 10 (negative control) prior to IMNV infection. Animals were inoculated with 2.0 mg dsRNA at day 0 and were challenged at day 10. (d) Survival of all treatment groups at termination of study (day 40). Positive control animals received an inoculation containing an equivalent volume of RNase-free water at day 0. Overall mortality at the termination of this experiment is shown in (d) for which y-axis indicates the per cent of survivors at day 40. Ten animals with weights of 3-5 g were used for each treatment (n510).
proteins were the targets of silencing in other RNA viruses such as YHV (Tirasophon et al., 2005; Yodmuang et al., 2006) . Non-specific dsRNA that was generated to a heterologous target (eGFP) did not have a positive impact on survival in animals challenged with IMNV, in contrast to what has been described with other shrimp viruses including TSV, YHV and WSSV (Robalino et al., 2004 (Robalino et al., , 2005 Westenberg et al., 2005; Yodmuang et al., 2006) . This may be due to differences in pathogenesis or viral replication mechanisms that are specific to IMNV. Additionally, this phenomenon may also be explained by differences in genome size; IMNV has a small genome relative to WSSV and TSV, and thus there may be reduced likelihood that the control dsRNA sequence would have sequence identity to the virus and thereby provide some degree of protection.
Another interesting observation from these efforts to optimize dsRNA antivirals is that sequences greater than 50 bp may be critical to induce the effect, because reduction in survival post-infection with IMNV was observed when the 194-275 (81 bp) dsRNA was truncated to 219-275 (56 bp) . This corresponds to a study that suggests that an RNAi trigger in L. vannamei has to be greater than 50 bp in length to stimulate transcription of the LvSid-1 gene, which encodes the protein involved in dsRNA transport into cells (Labreuche et al., 2010) .
Overall, these data demonstrate that by optimizing RNAi targets by beginning with larger sequences and moving through gradual truncations, the protective effect of dsRNA, on a per molecular mass basis, increases. dsRNA194-275 provides protection at a very small dose (0.02 mg), making it an ideal candidate antiviral molecule for delivery to shrimp for the purpose of preventing disease caused by IMNV. Previous reports wherein dsRNA was used to control WSSV disease showed protection with much larger quantities of dsRNA (~5.0 mg per gram of animal or higher) (Robalino at the termination of this experiment is shown for each of the dsRNAs (indicated according to fragment length). Three replicate tanks of 10 animals weighing 3-5 g were used for each treatment (n530) except the negative control for which there was a single tank (n510).
Developing a dsRNA antiviral for IMNV in shrimp et al., 2004) and quantities less than 1.0 mg were insufficient (Robalino et al., 2005) . This work demonstrates that vastly smaller amounts of specific dsRNA provide sufficient robust and long-term protection against IMNV disease (0.02 mg for 10 days).
The data also show that exposure to the optimized dsRNA produces long-term, specific immunity to subsequent challenge. For example, animals subjected to a low dose of dsRNA, and challenged 10 or 52 days later, in the latter case with 100-fold higher dose of virus, demonstrated significant protection against IMNV disease. This observation suggests that (i) RNAi may serve as a pseudo memory-type response that provides long-term protection from IMNV infection in shrimp or (ii) another mechanism of immunity, resulting from the initial exposure to virus and subsequent resolution of disease, provides resistance to subsequent challenges. Regardless of the mechanism, longterm protection is facilitated by the antiviral dsRNA that was critical to the animal's survival on first exposure to the virus and would prove to be a positive outcome in the field.
Here, we describe a process of defining IMNV genome dsRNA targets that provide shrimp protection from virus challenge. Optimization of target specificity, nucleotide length and dsRNA dosage level are key elements that support the potential economical use of RNAi triggers to protect shrimp from viral pathogens. Targets identified in this manner could be utilized in downstream efforts to develop therapeutics or vaccines for shrimp viral pathogens, either newly emerged or pre-existing.
METHODS
Animal rearing. Specific-pathogen-free (SPF) post-larvae were received from Shrimp Improvement Systems and reared in a biosecure animal holding facility at Iowa State University. Animals were placed into 1000 l tanks containing artificial seawater, an oystershell airlift biofilter and an activated carbon filter, and reared until 3-5 g in weight.
Preparation of virus inoculum. Based on a previously described methodology (Hasson et al., 1995) , tissue macerate from IMNV-infected animals free of other viruses was diluted 1 : 3 in sterile TN buffer (0.02 M Tris/HCl, 0.4 M NaCl, pH 7.4) and clarified through three centrifugation steps after which the supernatant was removed and subjected to subsequent centrifugation: (i) 4000 g for 30 min (ii) 15 000 g for 15 min (iii) 25 000 g for 60 min. The final supernatant was diluted 1 : 10 in 2 % saline and filtered to 0.2 microns. This stock viral clarification was aliquoted and frozen at 280 uC for challenge experiments. RT-qPCR analysis of RNA extracted following a freeze-thaw cycle indicated 3.2610 5 viral copy numbers ml 21 were present in the stock.
Determination of challenge dose. The optimum lethal dose by injection was tested in 20 (SPF) animals weighing 8-10 g. Each animal was injected with 100 ml stock, 1 : 10 or 1 : 100 dilutions thereof, or 2 % NaCl (sham) into the third abdominal segment. Using a 1 : 100 dilution, 100 % of shrimp died by 18 days p.i. as compared with the stock dilution that resulted in 100 % mortality between 1 and 2 days p.i., the 1 : 10 dilution which resulted in 100 % mortality at 11 days. The 100-fold dilution of the stock virus was used as the viral challenge dose for the described challenge experiments (Fig. 1) .
RT-qPCR. RT-qPCR was performed using methods adapted from a previous report (Andrade et al., 2007) . Briefly, RNA template was purified from 30 mg macerated muscle tissue and homogenized using a QIAShedder column (Qiagen) followed by extraction with an RNeasy Mini kit (Qiagen). RNA template (50 ml) was eluted from the column into RNase-free water and stored at 280 uC until the RTqPCR was performed. For qRT-PCR, reaction templates were thawed and boiled at 100 uC for 5 min prior to reverse transcription. One-
Step RT-PCR kit (Qiagen) was used. RNA template (2 ml) was mixed with 5 ml of 56Master Mix, 1 ml Enzyme Mix, 1 ml dNTP, 0.3 ml IMNV412F (20 mM), 0.3 ml IMNV545R (20 mM), 0.3 ml IMNVP1 (10 mM) (Supplementary Table S1 , available in JGV Online) and 15 ml RNase-free water for a total reaction volume of 25 ml. This reaction was then run in duplicate on a Bio-Rad CFX96 Real-time PCR Detection System under the following conditions RT for 30 min at 48 uC and 10 min at 95 uC, followed by PCR for 35 cycles of 15 s at 95 uC and 1 min at 60 uC. Viral copy number was calculated using CFX Manager Software (Bio-Rad) using an in vitro-transcribed RNA standard generated using methods similar to a previous report (Andrade et al., 2007) .
Statistical analysis. Statistical significance was conducted on mean log viral RNA copies ml 21 RNA and mean survival at days 12, 13 and 30 (termination of the experiment) using one-way ANOVA followed by Tukey's multiple comparison test using JMP 8 Software (SAS Institute Inc.).
dsRNA preparation. dsRNA was prepared using the Ambion Megascript RNAi kit following the manufacturer's instructions. To create cDNA template, RNA was extracted from virus-infected animals using a commercial nucleic acid purification kit (RNeasy Mini; Qiagen). Oligonucleotide primers for cDNA synthesis were then designed (GenBank accession no. EF061744) (Senapin et al., 2007) (Supplementary Table S1 ). Reverse transcription of RNA was performed by using Thermoscript-RT as per manufacturer's instructions (Invitrogen). Following reverse transcription, template cDNA (~50 ng) was added to a PCR master mix (PuReTaq Ready-To-Go PCR Beads; GE Healthcare) and thermal-cycling was performed using oligonucleotide primers (Supplementary Table S1 ) designed to specific regions of the IMNV genome (GenBank accession no. EF061744.1). Products were then cloned into pCR4.0 vectors (Zero Blunt TOPO PCR cloning kit; Invitrogen) and transformed into Escherichia coli (TOP10; Invitrogen). Plasmids preparations from these transformants were used as a template source for further PCRs to create DNA clones for RNA transcription. Each clone was sequenced and 100 % identity to the IMNV genome region of interest was confirmed. For synthesis of template for transcription, primers containing a T7 promoter sequence on the forward and reverse primer were used to amplify the segments of cDNA with flanking T7 promoter sites (Supplementary Table S1 ). PCR products were subjected to QIAquick (Qiagen) PCR clean-up to remove unincorporated dNTPs, oligonucleotide primers and enzyme. T7 DNA templates were then transcribed overnight following the manufacturer's directions. Following transcription, dsRNA products were incubated for 60 min with DNase I and RNase, and purified using the provided columns. dsRNA production was confirmed by gel electrophoresis in comparison with a molecular mass ladder (pGEM ladder; Promega) and the product was quantified by spectrophotometer.
Histopathology. Moribund animals that were found prior to death were fixed whole in Davidson's fixative (Bell & Lightner, 1988) for 24 h before being transferred to 70 % EtOH. In addition, two animals from each tank were anaesthetized in an ice slurry and fixed in Davidson's fixative (Bell & Lightner, 1988) , embedded in paraffin, cut into slide sections and stained with haematoxylin and eosin, and evaluated for the presence of IMNV lesions.
Shrimp bioassays. Tanks containing 200 l synthetic seawater and an oystershell airlift biofilter were stocked with 10 or 20 SPF juveniles weighing 3-7 g and allowed to acclimatize for 72 h. Tanks were maintained at 28 ppt salinity and 28 uC. Following acclimatization, animals were injected intramuscularly at the desired dose and volume of either dsRNA corresponding to regions of the IMNV genome, a heterologous dsRNA control or RNase-free water diluent. Following dsRNA administration, animals were challenged with IMNV intramuscularly (~3.2610 3 IMNV copy numbers ml 21 RNA) into the third abdominal segment at the desired time point (2, 10 or 52 days) or a sham virus challenge (2 % NaCl viral diluent) as a strict negative control. Animals were counted daily for mortality. Moribund animals were fixed for histopathology in some experiments. At the termination of experiments animals were euthanized by immersion in an ice water slurry and tissues from experiments were immediately frozen at 280 uC or fixed in Davidson's fixative for histopathology.
Target specificity. Tanks containing 20 SPF juveniles weighing 5-7 g were divided into five virus challenge groups with three replicates per group. Shrimp were injected with dsRNA constructs corresponding to three different segments of the IMNV genome, a heterologous dsRNA control (eGFP) or a sham vaccination. A total of 2.0 mg of in vitro-synthesized dsRNA was inoculated into animals that were then placed into randomized tanks. Animals were challenged with IMNV 48 h after dsRNA administration.
Dose-response. Tanks containing 10 animals weighing 3-5 g were divided into six experimental groups that received a dose (2.0, 0.2 or 0.02 mg) of a dsRNA construct (dsRNA95-475 or dsRNA3764-4805). Three control groups received a heterologous dsRNAeGFP at a single dosage of 2.0 mg of dsRNAeGFP. Following dsRNA administration, animals were challenged 2 days (data not shown) or 10 days later with IMNV.
Length dependency. Tanks containing 10 animals weighing 3-5 g were divided into treatment groups with three replicate tanks per treatment. Animals were subjected to injection with one of six dsRNA constructs corresponding to or different truncations of the . A total of 0.02 mg in vitro-synthesized dsRNA was inoculated into animals that were challenged 10 days later with IMNV.
Long-term protection. Shrimp administered 2.0 mg dsRNA95-475 that survived virus challenge from a prior experiment (n517) were subjected to a second infection at 100-fold higher dose of virus inoculum (~3.2610 5 IMNV copy numbers ml 21 RNA) ml RNA, 52 days after the initial virus challenge and 54 days after administration of dsRNA. A naïve challenge control group was injected with the same challenge dosage. Animals were followed for an additional 40 days after secondary challenge.
